Demant A/S

Demant A/S EBITDA per Share

The EBITDA per Share of Demant A/S (DEMANT.CO) as of Oct 8, 2026 is 25.79 DKK. In the previous year, EBITDA per Share was 28.24 DKK — a change of -8.66% (lower).

EBITDA per Share

25.79DKK

YoY

-8.66%

Last updated:

EBITDA per Share of Demant A/S is 2025 25.79 DKK. EBITDA per Share of Demant A/S was 2024 28.24 DKK. It decreases by -8.66% lower compared to the previous year.

The Demant A/S EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
10.68 DKK
Jan 1, 2019
9.63 DKK
Jan 1, 2020
9.08 DKK
Jan 1, 2021
15.76 DKK
Jan 1, 2022
19.08 DKK
Jan 1, 2023
23.87 DKK
Jan 1, 2024
28.24 DKK
Jan 1, 2025
25.79 DKK
The Demant A/S EBITDA per Share history
YEAREBITDA per ShareYoY
25.79DKK-8.66%
28.24DKK+18.32%
23.87DKK+25.11%
19.08DKK+21.05%
15.76DKK+73.56%
9.08DKK-5.74%
9.63DKK-9.83%
10.68DKK+12.04%
9.53DKK+23.35%
7.73DKK-1.04%
7.81DKK+9.62%
7.12DKK—
Access this data via the Eulerpool API

Demant A/S Stock analysis

What does Demant A/S do? Demant A/S is a Danish company that operates in the field of hearing technology. It was founded in 1904 and is headquartered in Smørum, Denmark. The company has several subsidiaries in various countries, including the USA, Germany, France, and China. The history of Demant began with the founding of the company Oticon by Hans Demant in Copenhagen in 1904. Oticon was the first company to manufacture and sell hearing aids. Since then, the company has evolved into a leading provider of hearing aids, cochlear implants, and assistive listening devices. Demant's business model is based on the development and marketing of hearing technology products. The company is divided into several business areas, including hearing aids, cochlear implants, and diagnostics and consumables. In the field of hearing aids, Demant offers a wide range of products tailored to the needs of different customer groups. These range from basic hearing aids to high-end products with artificial intelligence. Demant's cochlear implant system is a groundbreaking technology that enables deaf or hard-of-hearing individuals to hear. It consists of an implanted device and an external speech processor. Demant's diagnostics and consumables business includes a variety of products used by medical professionals for the diagnosis and treatment of hearing disorders. These include earplugs, audiometry devices, tympanometry devices, and others. Demant is also active in many other areas, including research, development, and production of hearing technology products. The company has a strong global network of partners, distributors, and customers that further strengthens its position as a leading provider of hearing technology products. Overall, Demant has developed a deep understanding of the needs and requirements of people with hearing problems through its commitment to excellence and innovation. With its wide range of products, global network, and deep commitment to customer satisfaction, Demant has become a trusted name in hearing technology. Demant A/S is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Demant A/S stock

EBITDA per Share of Demant A/S is 25.79 DKK in 2025.

EBITDA per Share of Demant A/S changed from 28.24 DKK to 25.79 DKK, representing a -8.66% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Demant A/S since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

Income Statement — Demant A/S

All Key Metrics — Demant A/S